Answers are grounded in this paper and cite their sources.
and accumulated in tumors. Furthermore, Fc-ARMs recruited antibodies to suppress tumor growth in a mouse model. Thus, Fc-ARMs have the potential to be a novel class of cancer immunotherapeutic agents.
No takes yet. Share an insight, caveat, or question.
Sasaki et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: